1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > InterMune, Inc. - Product Pipeline Review - 2014

InterMune, Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 40 pages

InterMune, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘InterMune, Inc. - Product Pipeline Review - 2014’, provides an overview of the InterMune, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of InterMune, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of InterMune, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of InterMune, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the InterMune, Inc.’s pipeline products

Reasons to buy

- Evaluate InterMune, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of InterMune, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the InterMune, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of InterMune, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of InterMune, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of InterMune, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

InterMune, Inc. - Product Pipeline Review - 2014
Table of Contents

InterMune, Inc. Snapshot 5
InterMune, Inc. Overview 5
Key Information 5
Key Facts 5
InterMune, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
InterMune, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
InterMune, Inc. - Pipeline Products Glance 12
InterMune, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
InterMune, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
InterMune, Inc. - Drug Profiles 15
pirfenidone 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ITMN-10534 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
ITMN-14440 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
ITMN-30162 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Small Molecule to Inhibit LOXL2 for Fibrosis 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
InterMune, Inc. - Pipeline Analysis 22
InterMune, Inc. - Pipeline Products by Target 22
InterMune, Inc. - Pipeline Products by Route of Administration 23
InterMune, Inc. - Pipeline Products by Molecule Type 24
InterMune, Inc. - Pipeline Products by Mechanism of Action 25
InterMune, Inc. - Recent Pipeline Updates 26
InterMune, Inc. - Dormant Projects 32
InterMune, Inc. - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
interferon gamma-1b (recombinant) 33
InterMune, Inc. - Company Statement 34
InterMune, Inc. - Locations And Subsidiaries 37
Head Office 37
Other Locations and Subsidiaries 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables

InterMune, Inc., Key Information 5
InterMune, Inc., Key Facts 5
InterMune, Inc. - Pipeline by Indication, 2014 7
InterMune, Inc. - Pipeline by Stage of Development, 2014 8
InterMune, Inc. - Monotherapy Products in Pipeline, 2014 9
InterMune, Inc. - Out-Licensed Products in Pipeline, 2014 10
InterMune, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 11
InterMune, Inc. - Phase II, 2014 12
InterMune, Inc. - Preclinical, 2014 13
InterMune, Inc. - Discovery, 2014 14
InterMune, Inc. - Pipeline by Target, 2014 22
InterMune, Inc. - Pipeline by Route of Administration, 2014 23
InterMune, Inc. - Pipeline by Molecule Type, 2014 24
InterMune, Inc. - Pipeline Products by Mechanism of Action, 2014 25
InterMune, Inc. - Recent Pipeline Updates, 2014 26
InterMune, Inc. - Dormant Developmental Projects,2014 32
InterMune, Inc. - Discontinued Pipeline Products, 2014 33
InterMune, Inc., Subsidiaries 37

List of Figures

InterMune, Inc. - Pipeline by Top 10 Indication, 2014 7
InterMune, Inc. - Pipeline by Stage of Development, 2014 8
InterMune, Inc. - Monotherapy Products in Pipeline, 2014 9
InterMune, Inc. - Pipeline by Top 10 Target, 2014 22
InterMune, Inc. - Pipeline by Top 10 Route of Administration, 2014 23
InterMune, Inc. - Pipeline by Top 10 Molecule Type, 2014 24
InterMune, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.